AbCellera Biologics Inc Ordinary Shares ABCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABCL is a good fit for your portfolio.
News
-
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
-
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
-
AbCellera Reports Q3 2023 Business Results
-
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
-
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
-
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
-
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
-
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
Trading Information
- Previous Close Price
- $4.73
- Day Range
- $4.69–5.03
- 52-Week Range
- $3.87–14.00
- Bid/Ask
- $4.75 / $4.86
- Market Cap
- $1.39 Bil
- Volume/Avg
- 2.5 Mil / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- 8.95
- Price/Sales
- 28.05
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 630
- Website
- https://www.abcellera.com
Valuation
|
Metric
|
ABCL
|
|---|---|
Price/Earnings (Normalized) | 8.95 |
Price/Book Value | 1.17 |
Price/Sales | 28.05 |
Price/Cash Flow | — |
Price/Earnings
ABCL
Financial Strength
|
Metric
|
ABCL
|
|---|---|
Quick Ratio | 7.81 |
Current Ratio | 8.34 |
Interest Coverage | — |
Quick Ratio
ABCL
Profitability
|
Metric
|
ABCL
|
|---|---|
Return on Assets (Normalized) | −5.16% |
Return on Equity (Normalized) | −6.50% |
Return on Invested Capital (Normalized) | −8.36% |
Return on Assets
ABCL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jphzh | $450.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xlpnm | $90.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zdjcly | $88.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Qbfdts | $40.3 Bil | |
MRNA
| Moderna Inc | Rmgmw | $30.1 Bil | |
ARGX
| argenx SE ADR | Fnxq | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Kmm | $23.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yckgx | $20.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Btjqml | $16.9 Bil | |
INCY
| Incyte Corp | Qqfhmlj | $12.0 Bil |